Watch this..!! 

  • Market cap $75M - Robust Pipeline - Acquisition value of similar companies in complement space with similar pipelines in the $1-2B+ range
  • 2 Phase 3 trials underway (fasttrack and orphan designations)
  • Eye data expected - $6-8B+ market
  • Whispers of multiple business developments on the way



Akari Therapeutics is also pursuing other earlier stage programs that are primarily focused on large disease areas with high unmet need and where complement and leukotriene pathways are implicated. For these programs, the Company is using alternative formulations to the subcutaneous delivery of nomacopan including topical, nebulized or long-acting engineered forms, which provide an opportunity for separate partnering options."